Law Firm Investigates Claims on Behalf of Investors of Dr. Reddy's Laboratories
Pomerantz LLP is investigating Dr. Reddy's Laboratories Limited for alleged securities fraud or other unlawful business practices. The probe follows a significant drop in the company's stock price.
Law firm Pomerantz LLP has launched an investigation into claims concerning investors of Dr. Reddy's Laboratories Limited. The investigation is examining whether the company and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
The probe was initiated following Dr. Reddy's Laboratories' announcement on July 22, 2026, regarding its first-quarter fiscal year 2027 earnings. The company reported earnings per share of only $0.06. This figure was impacted, in part, by a provision of ₹2.4 billion related to out-of-specification batches of semaglutide.
CEO Erez Israeli stated that the quarter's EBITDA margin was adversely affected by semaglutide-related issues, including lower sales, the provision for rejected batches, loss of production-linked incentives, and other associated costs. Following this news, Dr. Reddy's stock price fell by $1.18, or 9.4 percent, closing at $11.38 on July 22, 2026.
Pomerantz LLP, a firm specializing in class action litigation, is seeking investors who have suffered losses or have relevant information to contact Danielle Peyton to learn more about the investigation.